Sign up to save your podcasts
Or
Share English | Artificial Intelligence – what it can do and how we use it at Pfizer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
English | Artificial Intelligence – what it can do and how we use it at Pfizer
The use of AI is associated with many hopes for improved research and efficiency of a wide variety of processes. Pfizer's use of AI aims to support its corporate purpose. But what are we doing with AI in concrete terms? What is already possible today, what are we working on, and what does the future look like?
To discuss this, we speak with Dr. Ulrike Müller, who at the time was Medical Director Scientific Collaborations, and Dr. Daniel Kalanovic, who was Medical Director at Pfizer in Germany. Joining as well are Dr. Djörk-Arné Clevert, he leads Pfizer's global Machine Learning Hub from Berlin and Boston, and Thomas Kleine, who was the head of the Digital division at Pfizer in Germany.
Please note: This episode was previously published and has been translated using Artificial Intelligence to make the podcast accessible to a broader audience.
View all episodes
By PfizerThe use of AI is associated with many hopes for improved research and efficiency of a wide variety of processes. Pfizer's use of AI aims to support its corporate purpose. But what are we doing with AI in concrete terms? What is already possible today, what are we working on, and what does the future look like?
To discuss this, we speak with Dr. Ulrike Müller, who at the time was Medical Director Scientific Collaborations, and Dr. Daniel Kalanovic, who was Medical Director at Pfizer in Germany. Joining as well are Dr. Djörk-Arné Clevert, he leads Pfizer's global Machine Learning Hub from Berlin and Boston, and Thomas Kleine, who was the head of the Digital division at Pfizer in Germany.
Please note: This episode was previously published and has been translated using Artificial Intelligence to make the podcast accessible to a broader audience.